Summary: Genetic polymorphisms of enzymes involved in the metabolism of carcinogens are suggested to modify an individual's susceptibility to lung cancer. The purpose of this study was to investigate the relationship between lung cancer cases in Japan and variant alleles of cytochrome P450 (CYP) 2A6 (CYP2A6*4), CYP2A13 (CYP2A13*1-*10), CYP4B1 (CYP4B1*1-*7), sulfotransferase 1A1 (SULT1A1*2), glutathione S-transferase M1 (GSTM1 null), and glutathione S-transferase T1 (GSTT1 null). We investigated the distribution of these polymorphisms in 192 lung cancer patients and in 203 ageand sex-matched cancer-free controls. The polymorphisms were analyzed using various techniques including allele-specific PCR, hybridization probe assay, multiplex PCR, denaturing high-performance liquid chromatography (DHPLC), and direct sequencing. We also investigated allele and genotype frequencies and their association with lung cancer risk, demographic factors, and smoking status. The prevalence of the CYP2A6*4/*4 genotype in lung cancer cases was 3.6%, compared with 9.4% in the controls (adjusted OR = 0.36, 95% CI = 0.150.88, P = 0.025). In contrast, there was no association between the known CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1 polymorphisms and lung cancer. These data indicate that CYP2A6 deletions may be associated with lung cancer in the Japanese population studied.
Introduction
Lung cancer is a major cause of cancer-related death worldwide. 1¥ In Japan, lung cancer is the most common cause of death in the male population and the second most common cause of death in the female population, after colon cancer. Identifying the risk factors for lung cancer development is essential to prevent this deadly disease. Environmental exposure to tobacco smoke is the primary risk factor for lung cancer.
2,3¥ Tobacco smoke contains hundreds of known and probable carcinogens that are either activated or detoxified by xenobiotic metabolizing enzymes. In general, the metabolism of xenobiotics consists of phases I and II. Phase I enzymes, mainly cytochrome P450 ¤CYP¥, are typically involved in metabolic pathways involving activation of carcinogens, whereas phase II enzymes play a central role in detoxification.
Human CYP2A6 and CYP2A13 are important phase I enzymes involved in metabolizing nicotine and the metabolic activation of tobacco-specific nitrosamines such as 4-¤methyl-nitrosamino¥-1-¤3-pyridyl¥-1-butanone ¤NNK¥.
4,5¥ CYP2A6 is mainly expressed in the human liver, whereas CYP2A13 is selectively expressed in the human respiratory tract.
5, 6¥ To date, a large number of CYP2A6 and CYP2A13 genetic polymorphisms and alleles have been identified ¤http:// www.cypalleles.ki.se/¥. These alleles are derived from single nucleotide polymorphisms ¤SNPs¥ in regulatory and coding regions, deletions, insertions, and conversions. CYP2A6*4 is a major mutant allele associated with decreased metabolic activity. 7¥ Several studies have elucidated the role of the CYP2A6*4 allele in tobacco dependence and lung cancer risk. 8®10¥ Similarly, the CYP2A13 polymorphism 3375ChT has been correlated with a reduced risk of lung adenocarcinoma in a Chinese population.
11¥
CYP4B1 is primarily an extrahepatic form of P450. CYP4B1 mRNA has been detected in the human lung and bladder.
12,13¥ In animals, CYP4B1 is involved in the metabolism of several xenobiotics such as 2-aminofluorene, 2-naphthylamine, and benzidine.
14,15¥ To date, seven variant alleles of CYP4B1 have been identified in French Caucasian and Japanese individuals. We previously reported that the alleles CYP4B1*2 ¤AT881®882del, 993GhA, 1018ChT, and 1123ChT¥ and CYP4B1*3 ¤517ChT¥ are common in the Japanese population. 16¥ In particular, premature termination of protein synthesis by the double nucleotide deletion AT881®882del has been speculated to render the CYP4B1*2 allele non-functional. CYP4B1 genotypes may have an effect on the risk of bladder cancer; 17¥ however, it is unclear whether CYP4B1 polymorphisms are associated with lung cancer susceptibility.
Sulfotransferases ¤SULTs¥ appear to play an important role in phase II metabolism of xenobiotics, small endogenous compounds, and procarcinogenic agents. 18,19¥ Some studies have shown that genetic polymorphisms of SULT1A1 are associated with susceptibility to lung cancer.
20,21¥
Glutathione S-transferases ¤GSTs¥ are phase II enzymes that catalyze the conjugation of reactive intermediates to soluble glutathione. Some GSTs are polymorphic, and some genetic variants, such as GSTM1 null and GSTT1 null, may be associated with increased susceptibility to lung cancer.
22,23¥ Homozygous deletions of the GSTM1 and GSTT1 genes are common and result in complete loss of enzyme activity.
We conducted a case-control study to examine the association between the risk of lung cancer in Japanese individuals and P450s CYP2A6 ¤CYP2A6*4¥, CYP2A13 ¤CYP2A13*1-*10¥, CYP4B1 ¤CYP4B1*1-*7¥, sulfotransferase 1A1 ¤SULT1A1*2¥, glutathione S-transferase M1 ¤GSTM1 null¥, and glutathione S-transferase T1 ¤GSTT1 null¥ polymorphisms. In addition, we investigated the effect of smoking status and genetic combinations on the association between lung cancer risk and genetic polymorphisms.
Materials and Methods
Subject selection: From February 1995 to July 2003, 1,536 autopsies were performed at the Department of Pathology, Tokyo Metropolitan Geriatric Medical Center, Tokyo, Japan. DNA samples from 395 of these autopsies were analyzed in this case-control study; 192 lung cancer cases and 203 cancer-free controls were sex-and agematched. The smoking status of the individuals was retrospectively determined by reviewing medical records, and subjects were classified as smokers ¤including current smokers and ex-smokers¥ and non-smokers ¤individuals who have never smoked in their lifetime¥. Research protocols were approved by the Ethics Committees of Tokyo Metropolitan Geriatric Hospital and the Graduate School of Pharmaceutical Sciences, Tohoku University.
Genetic analysis: The presence of CYP2A6*4 ¤whole gene deletion¥ was determined by the two-step allele-specific PCR assay described by Oscarson et al. 24¥ The first step involved amplification of a region from exon 7 to approximately 420 bp downstream of exon 9 of CYP2A6 or the CYP2A6/CYP2A7 hybrid from all individuals with or without the deleted CYP2A6 gene. The reaction mixture contained approximately 30 ng genomic DNA, 0.5 µM of each primer ¤2AE7F, 5$-GGCCAAGATGCCCTACATG-3$; 2A6R1, 5$-GCACTTATGTTTTGTGAGACATCAGAGACAA-3$¥, 0.25 mM dNTPs, LA Taq polymerase ¤TaKaRa, Otsu, Japan¥, and 2' GC Buffer I ¤TaKaRa¥ in a total reaction volume of 16 µL. The thermal cycling conditions were as follows: 95ôC for 1 min; followed by 30 cycles of denaturation at 95ôC for 15 s, annealing at 60ôC for 20 s, extension at 72ôC for 3 min; and a final extension at 72ôC for 7 min. The PCR product was then used as a template in the second step, in which the deleted CYP2A6 gene was detected. PCR amplification was performed with 0.5 µL of the first PCR product, 0.25 µM forward primer ¤2A6E8F, 5$-CACTTCCTGAATGAG-3$, or 2A7E8F, 5$-CATTTCC-TGGATGAC-3$¥, 0.25 µM reverse primer ¤2A6R2, 5$-AAAATGGGCATGAACGCCC-3$¥, and 2' Amplitaq Gold PCR Master Mix ¤Applied Biosystems, Foster City, CA, USA¥ in a total volume of 20 µL. Thermal cycling conditions involved an initial denaturation at 95ôC for 10 min; followed by 16 cycles of denaturation at 95ôC for 30 s, annealing at 56ôC for 30 s, extension at 72ôC for 2 min; and a final extension at 72ôC for 7 min. Amplified products were analyzed by electrophoresis in 1% agarose gel. The presence of a CYP2A-specific 1181-bp product amplified with the 2A6E8F/2A6R2 primer pair indicated the presence of wildtype CYP2A6 ¤defined as CYP2A6 non*4 allele in this study¥. The product amplified from the primer pair 2A7E8F/2A6R2 indicated a CYP2A6 deletion ¤CYP2A6*4¥, and the presence of the product in both reactions from one individual indicated heterozygosity.
CYP2A13 genotypes were determined by our previously described assay. 25¥ Long PCR was performed in the first round to amplify exons 1®5 and 6®9 of the CYP2A13 gene using 10®50 ng of genomic DNA and LA-Taq DNA polymerase ¤TaKaRa¥. The thermal cycling consisted of an initial denaturation at 95ôC for 1 min; followed by 25 cycles of denaturation at 95ôC for 15 s, annealing at 68ôC or 65ôC for 20 s, and extension at 72ôC for 5 min; and then a final extension at 72ôC for 7 min. First-round PCR products were diluted 1:500 and used as templates for the second round of amplification for all CYP2A13 exons. The amplicons for each exon were generated using AmpliTaq Gold PCR Master Mix ¤Applied Biosystems¥. Second-round PCR comprised an initial denaturation at 95ôC for 10 min; followed by 25 cycles at 95ôC for 30 s, annealing at 60ôC for 30 s, and extension at 72ôC for 30 s; and then a final extension at 72ôC for 7 min. Heteroduplexes were generated by thermal cycling under the following conditions: 95ôC for 1 min, followed by 45 temperature decrements of 1.5ôC/min. PCR products were analyzed with the DHPLC system WAVE ¤Transgenomic Inc., Omaha, NE, USA¥. This involved separating PCR products ¤5 µL¥ on a heated C18 reverse-phase column using 0.1 M triethylammonium acetate ¤TEAA¥ in water and 0.1 M TEAA in 25% acetonitrile at a flow rate of 0.9 mL/min. The temperature for heteroduplex separation of a heterozygous CYP2A13 fragment was determined with the WAVE software, and the linear acetonitrile gradient was adjusted so that the retention time of the DNA peak was 3®5 min. The resultant chromatograms were compared with those of wild-type DNA, and both DNA strands were sequenced for samples in which variants were detected. CYP4B1*1 ¤wild-type¥, CYP4B1*2 ¤AT881-882del, 993GhA, 1018ChT, and 1123ChT¥, CYP4B1*3 ¤517ChT¥, CYP4B1*5 ¤993GhA¥, CYP4B1*6 ¤517ChT and 1033GhA¥, and CYP4B1*7 ¤AT881-882del, 993GhA, and 1018ChT¥ were also genotyped by the hybridization probe assay described by Sasaki et al. 17¥ Analysis of the distribution of the five polymorphisms ¤517ChT, AT881-882del, 993GhA, 1033GhA, and 1123ChT¥ allowed the characterization of six different CYP4B1 alleles. SULT1A1*1 ¤wild-type¥ and SULT1A1*2 ¤638GhA¥ were genotyped by a hybridization probe assay. The PCR mixtures contained 3 mM MgCl 2 , 0.5 µM each of the PCR primers, 0.4 µM of LC Red 640-labeled hybridization probes, 0.2 µM fluorescein isothiocyanate ¤FITC¥-labeled hybridization probes, 1 µM LightCycler DNA Master Hybridization Mix ¤Roche Diagnostics Inc., Mannheim, Germany¥, and approximately 30 ng of genomic DNA in a final volume of 10 µL. The thermal profile consisted of 30 s of initial denaturation at 95ôC, followed by 45 cycles at 95ôC for 1 s, annealing at 50ôC for 5 s, and extension at 72ôC for 5 s. The analytical melting program involved melting the PCR products at 95ôC for 30 s and at 40ôC for 30 s, followed by increasing the temperature to 80ôC at a ramp rate of 0.2ôC/s, with continuous fluorescence data collection.
GSTM1 and GSTT1 null ¤whole gene deletion¥ were identified by a multiplex PCR assay described by AbdelRahman et al. 26¥ Genomic DNA ¤10®50 ng¥ was amplified in a 20-µL reaction mixture containing 0.25 µM of each of the GSTM1 and GSTT1 primers. Exon 7 of the CYP1A1 gene was co-amplified as an internal control. Thermal cycling conditions comprised denaturation at 95ôC for 10 min; 30 cycles of denaturation at 95ôC for 30 s, annealing at 62ôC for 30 s, and extension at 72ôC for 30 s; and a final extension at 72ôC for 7 min. PCR products from co-amplification of the GSTM1, GSTT1, and CYP1A1 genes were analyzed by electrophoresis in 2% agarose gel. The GSTM1 and GSTT1 genes were detected by the presence or absence of a 215-bp ¤corresponding to GSTM1¥ or a 480-bp band ¤corresponding to GSTT1¥.
Statistical analysis: We evaluated the frequency distribution of patient characteristics, including sex, age, and smoking status, between the lung cancer cases and controls with the chi-squared and unpaired t-tests. HardyWeinberg equilibrium ¤HWE¥ was tested separately for each genotype in the cases and controls. The crude odds ratio ¤crude OR¥ and 95% confidence interval ¤95% CI¥ were used as estimates of the relative risk. The adjusted OR was calculated using binominal logistic regression to control for sex, age, and smoking status. A two-tailed P value g 0.05 indicated statistical significance. All statistical analyses were performed with Dr. SPSS software ¤Ver. 11.0.1¥.
Results
Cases and controls were classified according to sex, age, smoking status, and histological types of lung cancer ¤Table 1¥. The mean ages at the time of death were 80.3 + 7.9 years in lung cancer patients and 80.3 + 7.7 years in the cancer-free controls ¤P © 0.991¥. There were no statistically significant differences in sex distribution between the two groups ¤67.2% male cancer patients versus 69.0% male control patients, P © 0.705¥. More smokers were present in the cancer group compared with the control group ¤70.3% smokers among the cancer patients versus 51.7% smokers among the controls, P g 0.001¥. Of the 192 cancer patients, 41.7% had adenocarcinoma ¤AC¥, 24.5% had squamous cell carcinoma ¤SQCC¥, 21.4% had small-cell carcinoma ¤SCC¥, and 12.4% had other types of lung cancer.
The genotype distributions of CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1 in lung cancer cases and controls are summarized in Table 2 . The frequency of CYP2A6*4/*4 in cancer cases was significantly lower than that in the controls ¤adjusted OR © 0.36, 95% CI © 0.15®0.88, P © 0.025¥. Although the distribution of CYP2A13*1/*2 ¤9.4%¥ and *1/*3 ¤3.1%¥ in cancer cases was lower than that in the controls ¤12.3% and 3.9%, respectively¥, there was no significant association with lung cancer risk. In addition, the CYP4B1, SULT1A1, GSTM1, and GSTT1 genotypes were not associated with lung cancer risk. Table 3 summarizes the relationship between the CYP2A6 and CYP2A13 genotypes among lung cancer cases and controls, stratified by smoking status. There was a statistically significant association between smokers carrying CYP2A6*4/*4 and lung cancer risk ¤OR © 0.32, 95% CI © 0.10®0.99, P © 0.049¥. ORs were not calculated for non-smokers carrying CYP2A13*1/*2 and *1/*3, as the frequency was 0 in cancer cases. There was no statistically significant association between the CYP4B1, SULT1A1, GSTM1, and GSTT1 genotypes stratified by smoking status and lung cancer risk ¤data not shown¥. When stratifying by histological type, no significant association was found for any of the analyzed polymorphisms and lung cancer risk ¤data not shown¥.
Discussion
In this study, we observed that polymorphism of the CYP2A6 gene, but not of the CYP2A13, CYP4B1, SULT1A1, GSTM1, or GSTT1 genes, was associated with decreased risk of lung cancer in the Japanese population studied.
Defective CYP2A6 alleles have been associated with both increased and decreased risks of lung cancer in different ethnic groups. A Chinese lung cancer study suggested that the presence of the defective allele CYP2A6*4 increases lung cancer risk. 10¥ In contrast, a Japanese lung cancer study suggested that the presence of the CYP2A6*4 allele decreases the risk of lung cancer. 9¥ The results of our study were consistent with the latter study. CYP2A6 is responsible for the metabolic activation of NNK, one of the components of tobacco smoke. Reducing the production of ultimate carcinogens may lead to decreased DNA damage and reduced cancer development. This hypothesis was supported by a statistically significant association between smokers carrying CYP2A6*4/*4 and lung cancer risk.
To the best of our knowledge, this is the first case-control study evaluating the relationship between CYP2A13 genetic polymorphism and lung cancer risk in the Japanese population. CYP2A13 is highly active in the metabolic activation of several carcinogens. Thus, we speculated that reduction in enzymatic activity observed in the CYP2A13*2 ¤74GhA and 3375ChT¥ allelic variant could provide some protection against xenobiotic toxicity. Wang et al. reported that Chinese individuals carrying the variant CYP2A13 allele ¤3375CT or TT¥ have a reduced risk of lung adenocarcinoma in relation to light tobacco smoking, but protection against lung squamous cell carcinoma was not observed. 11¥ Timofeeva et al. found no significant association between CYP2A13 polymorphisms and lung cancer risk in Caucasian patients. 27¥ We also did not find significant association between the variant CYP2A13 allele and lung cancer. Interestingly, none of the non-smokers with lung cancer had the CYP2A13*2 or *3 alleles ¤Table 3¥. In nonsmoking individuals with low carcinogenic activity caused by CYP2A13 polymorphisms, the risk of lung cancer in the population may be much lower than that in smokers with CYP2A13 wild-type genotypes.
The effect of CYP4B1 polymorphisms on susceptibility of lung cancer has not previously been investigated. Our study is the first to provide evidence that CYP4B1 polymorphisms may not be associated with lung cancer risk. Our previous study indicated that CYP4B1 genotypes may affect bladder cancer risk. 17¥ Thus, the effect of the CYP4B1 polymorphism may differ among human organs with respect to cancer development.
Since SULT1A1 catalyzes the sulfation of numerous carcinogenic and mutagenic compounds such as heterocyclic and aromatic amines and polycyclic aromatic hydrocarbons, it was suggested that the reduction in enzymatic activity observed in SULT1A1*2 could affect the risk of lung cancer; however, the association between SULT1A1*2 and lung cancer risk was not statistically significant in this study. Nevertheless, Liang et al. conducted a study on 805 individuals with cancer and 809 control subjects in China, and demonstrated that the lung cancer risk was elevated among individuals with the SULT1A1*2 allele. 21¥ The reason for the discrepancy between our results and Liangös is unknown but may be related to differences in ethnicity, sample size, or environmental carcinogen exposure. 
AC, adenocarcinoma; SQCC, squamous cell carcinoma; SCC, small-cell carcinoma; ASQC, adenosquamous cell carcinoma; LCC, large cell carcinoma; SD, Standard deviation. In the present study, there was no statistically significant association between either the GSTM1 or GSTT1 genotype and lung cancer risk in the Japanese subjects studied. ToFigueras et al. reported that 14.4% of their cancer patients possessed homozygous deletion of both GSTT1 and GSTM1 ¤12.5% among healthy smokers¥, 28¥ suggesting no potentiation between null genotypes for lung cancer risk, which is in agreement with our results. In contrast, Pinarbasi et al.
23¥
and Kihara et al.
22¥ reported that GSTM1 null genotypes were associated with lung cancer risk in a Turkish population and in male Japanese smokers, respectively. These conflicting results, including ours, may be caused by some confounding factors such as ethnicity, selection of control group, characterization of cases, sample size, gene-gene and gene-environment interactions, and second-hand smoke conditions.
In conclusion, these results indicate that the CYP2A6*4/*4 genotypes, but not the CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1 gene polymorphisms, were associated with decreased risk of lung cancer in the Japanese population studied. However, there is an element of chance in the results in the present study because the sample size was relatively small. Therefore, further studies with larger sample sizes will be required to confirm the present findings. Binominal logistic regression analysis adjusted by sex and age.
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